BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29220359)

  • 1. Synthesis of novel purpurealidin analogs and evaluation of their effect on the cancer-relevant potassium channel KV10.1.
    Moreels L; Bhat C; Voráčová M; Peigneur S; Goovaerts H; Mäki-Lohiluoma E; Zahed F; Pardo LA; Yli-Kauhaluoma J; Kiuru P; Tytgat J
    PLoS One; 2017; 12(12):e0188811. PubMed ID: 29220359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thallium-sensitive fluorescent assay reveals loperamide as a new inhibitor of the potassium channel Kv10.1.
    Loza-Huerta A; Milo E; Picones A; Hernández-Cruz A; Luis E
    Pharmacol Rep; 2021 Dec; 73(6):1744-1753. PubMed ID: 34213738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the K
    Barriga-Montoya C; Huanosta-Gutiérrez A; Reyes-Vaca A; Hernández-Cruz A; Picones A; Gómez-Lagunas F
    Pflugers Arch; 2018 Mar; 470(3):491-503. PubMed ID: 29218452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chloroquine inhibits tumor-related Kv10.1 channel and decreases migration of MDA-MB-231 breast cancer cells in vitro.
    Valdés-Abadía B; Morán-Zendejas R; Rangel-Flores JM; Rodríguez-Menchaca AA
    Eur J Pharmacol; 2019 Jul; 855():262-266. PubMed ID: 31082369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dronedarone blockage of the tumor-related Kv10.1 channel: a comparison with amiodarone.
    Meléndez TA; Huanosta-Gutiérrez A; Barriga-Montoya C; González-Andrade M; Gómez-Lagunas F
    Pflugers Arch; 2020 Jan; 472(1):75-87. PubMed ID: 31897736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Dynamics-Derived Pharmacophore Model Explaining the Nonselective Aspect of K
    Toplak Ž; Merzel F; Pardo LA; Peterlin Mašič L; Tomašič T
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gating Modulation of the Tumor-Related Kv10.1 Channel by Mibefradil.
    Gómez-Lagunas F; Carrillo E; Pardo LA; Stühmer W
    J Cell Physiol; 2017 Aug; 232(8):2019-2032. PubMed ID: 27255432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APETx4, a Novel Sea Anemone Toxin and a Modulator of the Cancer-Relevant Potassium Channel K
    Moreels L; Peigneur S; Galan DT; De Pauw E; Béress L; Waelkens E; Pardo LA; Quinton L; Tytgat J
    Mar Drugs; 2017 Sep; 15(9):. PubMed ID: 28902151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procyanidin B1, a novel and specific inhibitor of Kv10.1 channel, suppresses the evolution of hepatoma.
    Na W; Ma B; Shi S; Chen Y; Zhang H; Zhan Y; An H
    Biochem Pharmacol; 2020 Aug; 178():114089. PubMed ID: 32533968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the pharmacological profile of κ-hefutoxin 1 and analogues: A focus on the inhibitory effect on the oncogenic channel K
    Moreels L; Peigneur S; Yamaguchi Y; Vriens K; Waelkens E; Zhu S; Thevissen K; Cammue BPA; Sato K; Tytgat J
    Peptides; 2017 Dec; 98():43-50. PubMed ID: 27578329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.
    Ganapathi SB; Kester M; Elmslie KS
    Am J Physiol Cell Physiol; 2009 Apr; 296(4):C701-10. PubMed ID: 19244476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin.
    Hartung F; Pardo LA
    Eur Biophys J; 2016 Oct; 45(7):709-719. PubMed ID: 27350552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kv10.1 potassium channel: from the brain to the tumors.
    Cázares-Ordoñez V; Pardo LA
    Biochem Cell Biol; 2017 Oct; 95(5):531-536. PubMed ID: 28708947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternatively Spliced Isoforms of KV10.1 Potassium Channels Modulate Channel Properties and Can Activate Cyclin-dependent Kinase in Xenopus Oocytes.
    Ramos Gomes F; Romaniello V; Sánchez A; Weber C; Narayanan P; Psol M; Pardo LA
    J Biol Chem; 2015 Dec; 290(51):30351-65. PubMed ID: 26518875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of 2,3-di- and 2,2,3-trisubstituted-3-methoxycarbonyl-γ-butyrolactones as potent antitumor agents.
    Le Floch C; Le Gall E; Sengmany S; Renevret P; Léonel E; Martens T; Cresteil T
    Eur J Med Chem; 2015 Jan; 89():654-70. PubMed ID: 25462273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
    Yu Z; Klaasse E; Heitman LH; Ijzerman AP
    Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel roles for hERG K(+) channels in cell proliferation and apoptosis.
    Jehle J; Schweizer PA; Katus HA; Thomas D
    Cell Death Dis; 2011 Aug; 2(8):e193. PubMed ID: 21850047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liensinine, a Novel and Food-Derived Compound, Exerts Potent Antihepatoma Efficacy via Inhibiting the Kv10.1 Channel.
    Ma B; Shi S; Guo W; Zhang H; Zhao Z; An H
    J Agric Food Chem; 2024 Mar; 72(9):4689-4702. PubMed ID: 38382537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
    Narayana Moorthy NS; Ramos MJ; Fernandes PA
    Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
    Huang XP; Mangano T; Hufeisen S; Setola V; Roth BL
    Assay Drug Dev Technol; 2010 Dec; 8(6):727-42. PubMed ID: 21158687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.